AstraZeneca COVID-19 vaccine carries a small risk of blood clots after the first injection. The second dose does not add to the risk of thrombosis, as the study by AstraZeneca shows. Reuters reports about this.
The study found that the risk of thrombosis as a side effect of the AstraZeneca Covid-19 vaccine is estimated at 8.1 per million after the first shot. After the second dose of the vaccine, branded Vaxzevria and invented by Oxford University, the rate was 2.3 per million, comparable to that seen in unvaccinated people.
The agency indicated that the AstraZeneca vaccine has a low additional risk of blood clots when combined with a low platelet count. Complete immunization with two doses does not increase the likelihood of this negative effect.
As it was reported earlier, research showed that the Pfizer and AstraZeneca Covid vaccines are highly effective against the Delta strain. High efficacy is observed after vaccination with two doses.